Product nameAnti-Prothrombin antibody [EPR20159]
See all Prothrombin primary antibodies
DescriptionRabbit monoclonal [EPR20159] to Prothrombin
Tested applicationsSuitable for: ICC/IF, Flow Cyt, WBmore details
Species reactivityReacts with: Human
Recombinant fragment within Human Prothrombin aa 300 to the C-terminus. The exact sequence is proprietary.
Database link: P00734
- WB: Human plasma and fetal liver lysate; HepG2 whole cell lysate. ICC/IF: HepG2 cells. Flow Cyt: HepG2 cells.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol, 0.05% BSA
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab208589 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000. Detects a band of approximately 72, 52, 33 kDa (predicted molecular weight: 70 kDa).|
FunctionThrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing.
Tissue specificityExpressed by the liver and secreted in plasma.
Involvement in diseaseDefects in F2 are the cause of factor II deficiency (FA2D) [MIM:613679]. It is a very rare blood coagulation disorder characterized by mucocutaneous bleeding symptoms. The severity of the bleeding manifestations correlates with blood factor II levels.
Genetic variations in F2 may be a cause of susceptibility to ischemic stroke (ISCHSTR) [MIM:601367]; also known as cerebrovascular accident or cerebral infarction. A stroke is an acute neurologic event leading to death of neural tissue of the brain and resulting in loss of motor, sensory and/or cognitive function. Ischemic strokes, resulting from vascular occlusion, is considered to be a highly complex disease consisting of a group of heterogeneous disorders with multiple genetic and environmental risk factors.
Defects in F2 are a cause of susceptibility to thrombosis (THR) [MIM:188050]. It is a multifactorial disorder of hemostasis characterized by abnormal platelet aggregation in response to various agents and recurrent thrombi formation. Note=A common genetic variation in the 3-prime untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increased risk of venous thrombosis.
Sequence similaritiesBelongs to the peptidase S1 family.
Contains 1 Gla (gamma-carboxy-glutamate) domain.
Contains 2 kringle domains.
Contains 1 peptidase S1 domain.
modificationsThe gamma-carboxyglutamyl residues, which bind calcium ions, result from the carboxylation of glutamyl residues by a microsomal enzyme, the vitamin K-dependent carboxylase. The modified residues are necessary for the calcium-dependent interaction with a negatively charged phospholipid surface, which is essential for the conversion of prothrombin to thrombin.
Cellular localizationSecreted > extracellular space.
- Information by UniProt
FormCleaved into the following 4 chains: 1. Activation peptide fragment 1 2. Activation peptide fragment 2 3. Thrombin light chain 4. Thrombin heavy chain
- coagulation factor II (thrombin) antibody
- Coagulation factor II antibody
- F2 antibody
All lanes : Anti-Prothrombin antibody [EPR20159] (ab208589) at 1/1000 dilution
Lane 1 : Human plasma at 20 µg
Lane 2 : Human fetal liver lysate at 20 µg
Lane 3 : HepG2 (Human liver hepatocellular carcinoma cell line) whole cell lysate at 10 µg
All lanes : VeriBlot for IP Detection Reagent (HRP) (ab131366) at 1/4000 dilution
Predicted band size: 70 kDa
Observed band size: 33,52,72 kDa why is the actual band size different from the predicted?
Exposure time: 3 minutes
Blocking/Dilution buffer: 5% NFDM/TBST.
Prothrombin is proteolytically cleaved into different fragments. The fragments profile is consistent with what has been described in the literature (PMID: 17637839; PMID: 21131592; PMID: 16734589).
Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized HepG2 (Human liver hepatocellular carcinoma cell line) cells labeling Prothrombin with ab208589 at 1/100 dilution, followed by Goat anti-rabbit IgG (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green). Confocal image showing cytoplasmic staining on HepG2 cell line.
The nuclear counter stain is DAPI (blue). Tubulin is detected with ab195889 (Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594)) at 1/200 dilution (red).
Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat anti-rabbit IgG (Alexa Fluor® 488) (ab150077) at 1/1000 dilution.
Flow cytometric analysis of 4% paraformaldehyde-fixed HepG2 (Human liver hepatocellular carcinoma cell line) cells labeling Prothrombin with ab208589 at 1/600 dilution (red) compared with a rabbit monoclonal IgG isotype control (ab172730; black) and an unlabelled control (cells without incubation with primary antibody and secondary antibody; blue). Goat anti rabbit IgG (Alexa Fluor® 488) at 1/2000 dilution was used as the secondary antibody.
ab208589 has not yet been referenced specifically in any publications.